SCHEMBL5578835

SCHEMBL5578835

O=C(c1ccccc1F)N1CC2(CCN(c3ccccc3Cl)CC2)c2cc(Cl)ccc21

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.49
ALDH1A1 P00352 3/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NPY2R P49146 1/20 0.41
HTT P42858 2/20 0.40
TSHR P16473 2/20 0.40
MGLL Q99685 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
AVPR1A P37288 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5578681 0.95 NOTUM (0.50) NOTUMALDH1A1L3MBTL1HTTTSHR
SCHEMBL5578689 0.90 NOTUM (0.49) NOTUMALDH1A1L3MBTL1HTTTSHR
SCHEMBL5578704 0.90 NOTUM (0.49) NOTUMALDH1A1L3MBTL1HTTTSHR
SCHEMBL5579107 0.89 NOTUM (0.48) NOTUMALDH1A1L3MBTL1HTTTSHR
SCHEMBL5578894 0.88 NOTUM (0.46) NOTUMALDH1A1L3MBTL1NPY2RHTT
SCHEMBL5777701 0.87 NOTUM (0.45) NOTUMALDH1A1L3MBTL1NPY2RHTT
SCHEMBL5578851 0.86 NOTUM (0.48) NOTUMALDH1A1L3MBTL1NPY2RHTT
SCHEMBL5578888 0.85 NOTUM (0.44) NOTUMALDH1A1L3MBTL1HTTTSHR
SCHEMBL5579066 0.84 NOTUM (0.43) NOTUMALDH1A1L3MBTL1HTTSMN1; SMN2
SCHEMBL5578596 0.82 NOTUM (0.46) NOTUMALDH1A1L3MBTL1HTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US claimed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof ARENA PHARMACEUTICALS, INC. (US) 2007-11-01 US disclosed
WO-2005063745-A9 NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF ARENA PHARM INC (US) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254903-A1 Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof REN, AVPR2, RECQL NOTUM 3318/4885ALDH1A1 634/4885L3MBTL1 4305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.